126344-09-0

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridine,1-ethyl-(9CI)
• Synonyms: 1H-Pyrrolo[2,3-b]pyridine,1-ethyl-(9CI);1-ethyl-1H-pyrrolopyridine
• CAS NO: 126344-09-0
• Molecular Formula: C₉H₁₀N₂
• Molecular Weight: 146.1891
• Product Categories: PYRIDINE
• Mol File: 126344-09-0.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridine,1-ethyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridine,1-ethyl-(9CI)(126344-09-0)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridine,1-ethyl-(9CI)(126344-09-0)

Safety Data

• Hazardous Substances Data: 126344-09-0(Hazardous Substances Data)

Usage

Heterocyclical structure

Pyridine ring fused to a pyrrole ring The compound has a unique structure with two heterocyclic rings, which are aromatic rings containing at least one nitrogen atom, fused together.

Use in pharmaceutical research

Building block for synthesis 1H-Pyrrolo[2,3-b]pyridine,1-ethyl-(9CI) is commonly used as an intermediate compound in the creation of various biologically active molecules.

Potential anti-cancer properties

Investigated for its possible role in anti-cancer drug development This compound has been researched for its potential to contribute to the creation of effective cancer treatments.

Dopaminergic agonist

Possible treatment for Parkinson's disease As a dopaminergic agonist, this compound may have therapeutic potential in managing the symptoms of Parkinson's disease by mimicking the action of dopamine in the brain.

1-ethyl substituent

Adds steric hindrance The presence of an ethyl group on the pyrrolopyridine ring introduces steric hindrance, which may affect the compound's binding affinity and activity within biological systems.

Versatility in medicinal chemistry

Potential applications in drug discovery Due to its unique structure and properties, 1H-Pyrrolo[2,3-b]pyridine,1-ethyl-(9CI) is a valuable compound for exploring new drug candidates and advancing the field of medicinal chemistry.

Upstream product

• 271-63-6 7-Azaindole 
• 74-96-4 ethyl bromide 
• 75-03-6 ethyl iodide 

Downstream Products

• 1613252-40-6 (E)-2-(1-ethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzaldehyde O-methyl oxime 
• 1225584-88-2 4-[4-(1-ethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamino]phenol 
• 281192-95-8 1-ethyl-7-aza-isatin 
• 141650-50-2 1-ethyl-1H-pyrrolo<2,3-b>pyridine-3-carbaldehyde 

Relevant articles and documents

Halogen Bond-Assisted Electron-Catalyzed Atom Economic Iodination of Heteroarenes at Room Temperature

A halogen bond-assisted electron-catalyzed iodination of heteroarenes has been developed for the first time under atom economic condition at room temperature. The iodination is successful with just 0.55 equiv of iodine and 0.50 equiv of peroxide. The kinetic study indicates that the reaction is elusive in the absence of a halogen bond between the substrate and iodine. The formation of a halogen bond, its importance in lowering the activation barrier for this reaction, the presence of radical intermediates in a reaction mixture, and the regioselectivity of the reaction have been demonstrated with several control experiments, spectroscopic analysis, and quantum chemical calculations. Allowing the formation of the halogen bond may offer a new strategy to generate the reactive radical intermediates and to enable the otherwise elusive electron-catalyzed reactions under mild reaction conditions.

KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS

Described herein are compounds that are inhibitors of one or more protein kinases. Also described are pharmaceutical compositions and medicaments that include the compounds described herein. Also described herein are methods of using such protein kinase inhibitors, alone and in combination with other compounds, for conditions or diseases mediated or dependent upon protein kinases

Potent platelet-derived growth factor-β receptor (PDGF-βR) inhibitors: Synthesis and structure-activity relationships of 7-[3-(cyclohexylmethyl)ureido]-3-{1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl} quinoxalin-2(1H)-one derivatives

We found previously that 7-[3-(cyclohexylmethyl)ureido]-3-{1-methyl-1H- pyrrolo[2,3-b]pyridin-3-yl}quinoxalin-2(1H)-one (7d-6) has considerable potency as a PDGF inhibitor. This compound showed potent inhibitory activity in a PDGF-induced CPA (Cell Proliferation Assay) and APA (Auto-Phosphorylation Assay) (IC50=0.05 μmol/l in CPA, 0.03 μmol/l in APA). Therefore, we tried to develop a novel and effective PDGF-βR inhibitor by optimizing a series of its derivatives. We found that trifluoroacetic acid (TFA)-catalyzed coupling of pyrrolo[2,3-b]pyridines with quinoxalin-2-ones proceeded efficiently under mild oxidation condition with manganese(IV) oxide (MnO2) in situ, so this method was applied to prepare a series of derivatives. Results of in vitro screening of newly synthesized derivatives identified compound 7d-9 as having potent (IC50=0.014 μmol/l in CPA, 0.007 μmol/l in APA) and selective [IC50 values against vascular endothelial growth factor receptor 2 (VEGFR2, kinase domain region, KDR), epidermal growth factor receptor (EGFR), c-Met (hepatocyte growth factor receptor) and insulin growth factor I receptor (IGF-IR)/IC50 against PDGFR were each >1000] inhibitory activity. Moreover, in this series of derivatives, 7b-2 showed potent inhibitory activity toward both PDGF- and VEGF-induced signaling (PDGFR: IC50=0.004 μmol/l in CPA, 0.0008 μmol/l in APA, KDR: IC 50=0.008 μmol/l in APA). Herein we report a new and convenient synthetic method for this series of derivatives and its SAR study.